The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
August 29th 2025
A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.
Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease
January 15th 2025The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.
Syn-One Test Displays Significant Clinical Utility for the Diagnosis of Synucleinopathies
December 22nd 2024Since the Syn-One Test only needs a small punch skin biopsy that can be collected in an office setting, the clinical utility can be enhanced to offer more geographically convenient access for patients earlier in the disease.
Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes
December 20th 2024Although the primary goal was not met, prasinezumab demonstrated encouraging effects on secondary and exploratory measures, such as time to worsening motor function, Clinical Global Impression of Change, MDS-UPDRS motor scores.
Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
December 3rd 2024To date, BT-267 shows strong potential as a best-in-class LRRK2 inhibitor for Parkinson disease, with a superior safety profile, excellent pharmacokinetics, and innovative development leveraging advanced technologies and biomarker modeling.
StrivePD: Revolutionizing Parkinson Disease Care Through Data and Personalization
November 23rd 2024Amanda Hare, DNP, a doctor of nursing practice specialized in movement disorders, gave comments on the innovation behind the StrivePD app and how it can revolutionize personalized treatment management for patients with Parkinson disease.
Coupling Eye Movements and Postural Sway Significantly Enhances Stability in Parkinson Disease
November 22nd 2024Findings from a recently published study suggest patients with Parkinson disease can reduce postural sway as efficiently as neurologically healthy patients when performing horizontal saccades.
VQ-101 Show Promise in Interim Phase 1 Data for GBA-Parkinson Disease Treatment
November 16th 2024According to the company, VQ-101 is the first small molecule to show over 75% activation of the lysosomal enzyme GCase in humans, with phase 1 results in healthy volunteers indicating tolerability and exposure levels that support once-daily dosing.
GAD-Related Parkinson Gene Therapy AAV-GAD Demonstrates Efficacy in Topline Findings
November 14th 2024Initial findings showed significant improvements from baseline in the disease-specific, patient-reported quality of life scores in both the high and low dose AAV-GAD groups, with no significant change in the sham group at 26 weeks.
Using Data Collection to Improve Parkinson Disease Treatment Personalization: Amanda Hare, DNP
November 14th 2024The doctor of nursing practice specialized in movement disorders discussed specific data the StrivePD app captures and how it can enhance quality of life for patients with Parkinson disease. [WATCH TIME: 3 minutes]
Therapeutic Advantages of StrivePD for Parkinson Disease Management: Amanda Hare, DNP
November 13th 2024The doctor of nursing practice specialized in movement disorders provided clinical insight on how the StrivePD application empowers patients with Parkinson disease to track symptoms, medication, and daily activities using an iPhone and Apple Watch. [WATCH TIME: 3 minutes]
The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial
October 25th 2024David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease.
FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment
Published: October 17th 2024 | Updated: October 21st 2024In clinical trials, patients with Parkinson disease who were treated with foscarbidopa/foslevodopa experienced superior improvement in ON time without dyskinesia compared with oral immediate-release carbidopa/levodopa.
Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease
October 14th 2024Jonas Hannestad, MD, PhD, chief medical officer at Gain Therapeutics, provided clinical perspective on promising data from a phase 1 first-in-human study of GT-02287, an investigational therapy for Parkinson disease with or without a GBA1 mutation.
Mechanism of Stem Cell Therapy Bemdaneprocel for Parkinson Disease: Amit Rakhit, MD
October 9th 2024The chief medical officer and chief development officer at BlueRock Therapeutics discussed the promise behind bemdaneprocel and its unique mechanism of action relative to other Parkinson disease treatments. [WATCH TIME: 3 minutes]